Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Medical Breakthroughs from Penn Medicine

Diagnosing Gastrointestinal Neuroendocrine Tumors

ReachMD Healthcare Image
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    Although gastroenteropancreatic neuroendocrine tumors, or GEP-NETs, are relatively common, they are often indolent. However, GEP-NETs can metastasize in a small portion of the population, so physicians should be aware of symptoms and screening tools. The two most common types of GEP-NETs are categorized as carcinoids and pancreatic endocrine tumors. What distinguishes the two? Host Dr. Lee Freedman welcomes Dr. David Metz, professor of medicine and associate chief for clinical affairs in the division of gastroenterology at Penn Medicine, to discuss characteristics and diagnosis of GEP-NETs.

    Produced in Cooperation with

    Penn Medicine

Recommended
Details
Presenters
Comments
  • Overview

    Although gastroenteropancreatic neuroendocrine tumors, or GEP-NETs, are relatively common, they are often indolent. However, GEP-NETs can metastasize in a small portion of the population, so physicians should be aware of symptoms and screening tools. The two most common types of GEP-NETs are categorized as carcinoids and pancreatic endocrine tumors. What distinguishes the two? Host Dr. Lee Freedman welcomes Dr. David Metz, professor of medicine and associate chief for clinical affairs in the division of gastroenterology at Penn Medicine, to discuss characteristics and diagnosis of GEP-NETs.

    Produced in Cooperation with

    Penn Medicine

Schedule14 Dec 2024